Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (81-90 of 668) with videos related to

Pageof 67
Sort By:
Drugs|October 12, 2013
Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guideFernando Gomollón, Javier P Gisbert
Gastroenterologia Y Hepatologia|May 12, 2007
[Common errors in the management of the seriously ill patient with inflammatory bowel disease]Javier P Gisbert, Fernando Gomollón
The American Journal of Gastroenterology|January 29, 2009
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a reviewJavier P Gisbert, Julián Panés
Expert Opinion on Drug Safety|September 23, 2014
How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?María Chaparro, Javier P Gisbert
Gastroenterologia Y Hepatologia|March 8, 2016
Efficacy and safety of vedolizumab in the treatment of ulcerative colitisEugeni Domènech, Javier P Gisbert
Expert Opinion on Pharmacotherapy|May 31, 2016
Maintenance therapy options for ulcerative colitisMaría Chaparro, Javier P Gisbert
Gastroenterologia Y Hepatologia|December 4, 2015
[New molecules in the treatment of inflammatory bowel disease]María Chaparro, Javier P Gisbert
Gastroenterologia Y Hepatologia|May 14, 2018
Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic reviewJavier P Gisbert, María Chaparro
Drugs|July 28, 2023
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's DiseaseJavier P Gisbert, María Chaparro
Helicobacter|May 20, 2003
Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatmentJavier P Gisbert, José María Pajares
Pageof 67

Showing results (81-90 of 668) with videos related to

Sort By:
Pageof 67
Drugs|October 12, 2013
Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guideFernando Gomollón, Javier P Gisbert
Gastroenterologia Y Hepatologia|May 12, 2007
[Common errors in the management of the seriously ill patient with inflammatory bowel disease]Javier P Gisbert, Fernando Gomollón
The American Journal of Gastroenterology|January 29, 2009
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a reviewJavier P Gisbert, Julián Panés
Expert Opinion on Drug Safety|September 23, 2014
How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?María Chaparro, Javier P Gisbert
Gastroenterologia Y Hepatologia|March 8, 2016
Efficacy and safety of vedolizumab in the treatment of ulcerative colitisEugeni Domènech, Javier P Gisbert
Expert Opinion on Pharmacotherapy|May 31, 2016
Maintenance therapy options for ulcerative colitisMaría Chaparro, Javier P Gisbert
Gastroenterologia Y Hepatologia|December 4, 2015
[New molecules in the treatment of inflammatory bowel disease]María Chaparro, Javier P Gisbert
Gastroenterologia Y Hepatologia|May 14, 2018
Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic reviewJavier P Gisbert, María Chaparro
Drugs|July 28, 2023
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's DiseaseJavier P Gisbert, María Chaparro
Helicobacter|May 20, 2003
Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatmentJavier P Gisbert, José María Pajares
Pageof 67